| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Center for Molecular Imaging, Massachusetts General Hospital, and 2 Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
Requests for reprints: Khalid Shah, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129. Phone: 617-726-4821; Fax: 617-726-5708; E-mail: kshah{at}helix.mgh.harvard.edu.
Despite the development of new glioma therapies that allow for tumor-targeted in situ delivery of cytotoxic drugs, tumor resistance to apoptosis remains a key impediment to effective treatment. Mounting evidence indicates that microRNAs (miRNA) might play a fundamental role in tumorigenesis, controlling cell proliferation and apoptosis. In gliomas, microRNA-21 (miR-21) levels have been reported to be elevated and their knockdown is associated with increased apoptotic activity. We hypothesized that suppression of miR-21 might sensitize gliomas for cytotoxic tumor therapy. With the use of locked nucleic acid (LNA)-antimiR-21 oligonucleotides, bimodal imaging vectors, and neural precursor cells (NPC) expressing a secretable variant of the cytotoxic agent tumor necrosis factor–related apoptosis inducing ligand (S-TRAIL), we show that the combined suppression of miR-21 and NPC-S-TRAIL leads to a synergistic increase in caspase activity and significantly decreased cell viability in human glioma cells in vitro. This phenomenon persists in vivo, as we observed complete eradication of LNA-antimiR-21–treated gliomas subjected to the presence of NPC-S-TRAIL in the murine brain. Our results reveal the efficacy of miR-21 antagonism in murine glioma models and implicate miR-21 as a target for therapeutic intervention. Furthermore, our findings provide the basis for developing combination therapies using miRNA modulation and cytotoxic tumor therapies. [Cancer Res 2007;67(19):8994–9000]
This article has been cited by other articles:
|
|
 |
|
  S M Metias, E Lianidou, and G M Yousef MicroRNAs in clinical oncology: at the crossroads between promises and problems J. Clin. Pathol., September 1, 2009; 62(9): 771 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sotiropoulou, G. Pampalakis, E. Lianidou, and Z. Mourelatos Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell RNA, August 1, 2009; 15(8): 1443 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ueda, G. Kohanbash, K. Sasaki, M. Fujita, X. Zhu, E. R. Kastenhuber, H. A. McDonald, D. M. Potter, R. L. Hamilton, M. T. Lotze, et al. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1 PNAS, June 30, 2009; 106(26): 10746 - 10751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Huse, C. Brennan, D. Hambardzumyan, B. Wee, J. Pena, S. H. Rouhanifard, C. Sohn-Lee, C. le Sage, R. Agami, T. Tuschl, et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo Genes & Dev., June 1, 2009; 23(11): 1327 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhuang, Z. Qin, and Z. Liang The role of autophagy in sensitizing malignant glioma cells to radiation therapy Acta Biochim Biophys Sin, May 1, 2009; 41(5): 341 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Weinberg and M. J.A. Wood Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics Hum. Mol. Genet., April 15, 2009; 18(R1): R27 - R39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Sasportas, R. Kasmieh, H. Wakimoto, S. Hingtgen, J. A. J. M. van de Water, G. Mohapatra, J. L. Figueiredo, R. L. Martuza, R. Weissleder, and K. Shah Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy PNAS, March 24, 2009; 106(12): 4822 - 4827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zeng Regulation of the Mammalian Nervous System by MicroRNAs Mol. Pharmacol., February 1, 2009; 75(2): 259 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Amaral, N. Torres, F. Saggioro, L. Neder, H. R. Machado, W. A. Silva Jr, A. C. Moreira, and M. Castro MicroRNAs Differentially Expressed in ACTH-Secreting Pituitary Tumors J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 320 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hingtgen, X. Ren, E. Terwilliger, M. Classon, R. Weissleder, and K. Shah Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide Mol. Cancer Ther., November 1, 2008; 7(11): 3575 - 3585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Papagiannakopoulos, A. Shapiro, and K. S. Kosik MicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells Cancer Res., October 1, 2008; 68(19): 8164 - 8172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gabriely, T. Wurdinger, S. Kesari, C. C. Esau, J. Burchard, P. S. Linsley, and A. M. Krichevsky MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators Mol. Cell. Biol., September 1, 2008; 28(17): 5369 - 5380. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
